Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-019939
Filing Date
2025-02-13
Accepted
2025-02-13 16:30:02
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5499
  Complete submission text file 0000950170-25-019939.txt   7061
Mailing Address 11080 CIRCLEPOINT RD., STE, 200 WESTMINSTER CO 80020
Business Address
BERNS PAUL L (Filed by) CIK: 0001202769 (see all company filings)

Type: SCHEDULE 13G/A

Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Subject) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94162 | Film No.: 25620745
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)